CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health has opted not to cover Gilead Sciences' new FDA-approved, twice-yearly HIV prevention drug, Yeztugo, on its commercial and ACA formularies, citing clinical, financial, and regulatory factors for the drug priced over $28,000 annually. This rejection, which has drawn criticism and impacted Gilead's premarket stock, occurs as CVS faces significant legal pressure, including recent federal judgments totaling over $1.2 billion against its Caremark and Omnicare units for Medicare fraud and fraudulent billing. The decision highlights the ongoing tension in drug pricing and formulary management for high-cost therapies amidst increased scrutiny on pharmacy benefit managers.

Analysis

CVS Health's decision to exclude Gilead Sciences' newly approved HIV prevention drug, Yeztugo, from its commercial and ACA formularies introduces a significant commercial barrier for Gilead. Citing clinical, financial, and regulatory factors, CVS is leveraging its position as a major pharmacy benefit manager (PBM) to challenge Yeztugo's high annual list price of over $28,000, particularly as the drug is not yet included in the U.S. Preventive Services Task Force's recommendations for mandatory coverage. This setback for Gilead, reflected in a 2.71% premarket stock decline, is countered by the company's confident outlook, projecting 90% insurer coverage by mid-2026 and citing analyst support for the drug's multi-billion dollar potential. The move by CVS occurs amidst intense legal pressure on its own business, with its Caremark and Omnicare units facing combined judgments of over $1.2 billion for Medicare fraud and fraudulent billing. While CVS plans to appeal, these legal issues represent a material financial and reputational risk, contributing to a highly negative sentiment score (-0.8) for the company and underscoring the broader industry tensions between drug pricing, PBM cost-containment, and patient access.

Key Decisions for Investors

• Investors in Gilead (GILD) should view the CVS rejection as a near-term commercial hurdle and must now closely monitor the company's progress toward its stated 2025-2026 coverage targets with other insurers, as success here is critical to validating Yeztugo's long-term revenue potential.
• For CVS investors, the primary concern is the escalating legal risk, with over $1.2 billion in recent judgments for fraud; closely tracking the appeals process and any further regulatory scrutiny is more material than this single formulary dispute.
• This conflict reinforces the significant market power of PBMs in acting as gatekeepers for high-priced drugs, a key risk for biotech innovators, while simultaneously providing a near-term competitive advantage to Pfizer and GSK, whose alternative PrEP drug remains covered by CVS.